Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463511 | 0.84 | CSNK1D (0.44) | KDM4EKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19492615 | 0.81 | KDM4E (0.40) | KDM4EKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20768126 | 0.78 | ALDH1A1 (0.35) | PPARAKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20768144 | 0.77 | PDE2A (0.52) | KMT2AALDH1A1POLB | |
| SCHEMBL28619643 | 0.72 | KDM4E (0.42) | PPARAKDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL19463979 | 0.71 | KEAP1 (0.40) | KDM4EKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19492644 | 0.70 | ALDH1A1 (0.40) | KDM4EKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19463245 | 0.68 | ALDH1A1 (0.42) | PPARAKDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL8140882 | 0.66 | KDM4E (0.39) | PPARAKDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL19463663 | 0.66 | KDM4E (0.50) | KDM4EKMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442974-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| CN-109071545-B | Novel pyrazolopyrimidine derivatives | 拜耳动物保健有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-07-30 | — | — | US | disclosed |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-07-30 | — | — | US | disclosed |
| US-10604525-B2 | Pyrazolopyrimidine derivatives | BAYAL ANIMAL HEALTH GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
| EP-3442974-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017178416-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| US-9408927-B2 | Contrast agents for applications including perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2016-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604525-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | PPARA 2978/4885KDM4E 1438/4885KMT2A 2398/4885 |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | PPARA 2995/4885KDM4E 1445/4885KMT2A 2383/4885 |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | PPARA 2978/4885KDM4E 1438/4885KMT2A 2398/4885 |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | PPARA 2995/4885KDM4E 1445/4885KMT2A 2383/4885 |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | PPARA 2995/4885KDM4E 1445/4885KMT2A 2383/4885 |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | PPARA 2990/4885KDM4E 1658/4885KMT2A 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.